Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 9 recruiting now early-phase tilt

Anal Cancer: early-phase trial registry

9 of 21 indexed Anal Cancer trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #797 of 28,707 conditions by registered trial count.

21 US clinical trials · 9 currently recruiting · #797 of 28,707 conditions by registered trial count

Anal Cancer: 21 US clinical trials tracked, 9 recruiting.

Anal Cancer is the subject of 21 registered US clinical trials on ClinicalTrials.gov, 9 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 10 in Phase 1-2 (earlier-stage). The most active sponsor is National Cancer Institute (NCI), running 4 of these trials.

Enrollment posture brief

Registry condition anal-cancer

OPEN 9 | RECR 43% | LATE 2 | EARLY 10 | RANK #797 | SPON 4

Nearest open-share peer: Acute Myelogenous Leukemia (AML) (43% recruiting · 7 trials)

Anal Cancer (this)43%Allergic Conjunctivitis14.3%Attention Deficit Disorder W4.8%Autism Spectrum Disorders4.8%Adult Acute Myeloid Leukemia0%
Open-enrollment share among volume-matched conditions near Anal Cancer

Anal Cancer lists 9 open slots (43% of 21 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Anal Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Anal Cancer is recruiting above its size-band peers.

    9 of 21 indexed trials (42.9%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Anal Cancer research.

    National Cancer Institute (NCI) accounts for 4 of 21 trials (19%). 18 distinct sponsors appear on at least one study for this condition label.

  3. Most Anal Cancer trials plan to enrol fewer than 100 people.

    Median target enrolment is 51 among the 20 trials that report a genuine target (sentinel values excluded). 13 of those (65%) plan for fewer than 100 participants.

  4. Anal Cancer research is mostly interventional.

    15 interventional and 6 observational studies make up this index (71.4% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 15Phase 25Phase 32

Open and recent trials

21 total, page 1 of 1

RECRUITING open-ended (no fixed target)

Integrated Cancer Repository for Cancer Research

University of Nebraska

NCT02012699

RECRUITING 5,000 participants

Assessing THE GAY Male Experience With Anal Cancer Prevention Strategies

University of Minnesota

NCT05628194

RECRUITING NA 572 participants

Self-sampling to Optimize Anal Lesion Outcomes

Medical College of Wisconsin

NCT07192055

RECRUITING NA 200 participants

EQUITY GI: A Prospective Study to Enhance Quality, Inclusivity, and Trial Participation in Black Patients With Gastrointestinal Cancer.

Case Comprehensive Cancer Center

NCT06263088

RECRUITING 100 participants

DESTINY-PANTUMOUR04

AstraZeneca

NCT07124000

RECRUITING Phase 2 23 participants

Study of Pembrolizumab, Carboplatin, Paclitaxel, and Radiation for the Treatment of Early-Stage Anal Cancer

Dustin Deming

NCT06493019

RECRUITING Phase 2 20 participants

E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers

Christian Hinrichs

NCT05686226

RECRUITING 20 participants

Detecting HPV DNA in Anal and Cervical Cancers

University of Chicago

NCT04857528

RECRUITING 10 participants

Ovarian-Sparing Adaptive Radiotherapy in Young Adult Women

Washington University School of Medicine

NCT06904365

ACTIVE NOT RECRUITING Phase 1 126 participants

A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers

Novartis Pharmaceuticals

NCT05544929

ACTIVE NOT RECRUITING Phase 1 55 participants

A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers

National Cancer Institute (NCI)

NCT04708470

ACTIVE NOT RECRUITING Phase 1 51 participants

Combination Immunotherapy in Subjects With Advanced HPV Associated Malignancies

National Cancer Institute (NCI)

NCT04287868

ACTIVE NOT RECRUITING Phase 1 39 participants

HPV Vaccine PRGN-2009 Alone or in Combination With Anti-PDL1/TGF-Beta Trap (M7824) in Subjects With HPV Associated Cancers

National Cancer Institute (NCI)

NCT04432597

ACTIVE NOT RECRUITING Phase 2 33 participants

REDEL Trial: Reduced Elective Nodal Dose for Anal Cancer Toxicity Mitigation

University of Cincinnati

NCT05902533

COMPLETED Phase 3 4,446 participants

Treatment in Preventing Anal Cancer in Patients With HIV and Anal High-Grade Lesions

AIDS Malignancy Consortium

NCT02135419

COMPLETED Phase 3 161 participants

Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors

Dan Zandberg

NCT04157985

COMPLETED Phase 2 63 participants

Intensity-Modulated Radiation Therapy, Fluorouracil, and Mitomycin C in Treating Patients With Invasive Anal Cancer

Radiation Therapy Oncology Group

NCT00423293

COMPLETED Phase 2 38 participants

Pembrolizumab in Metastatic Anal Cancer

Dana-Farber Cancer Institute

NCT02919969

COMPLETED NA 29 participants

Videoscopic Versus Open Inguinal Lymphadenectomy for Cancer

Emory University

NCT01526486

COMPLETED Phase 1 18 participants

SGN-00101 in Preventing Anal Cancer in Patients With HIV Who Have Anal Neoplasia

National Cancer Institute (NCI)

NCT00052897

COMPLETED 14 participants

Radiation Dosimetry Study Comparing 2 Different Patient Setups in Anal/Rectal Cancer Patients

The University of Texas Medical Branch, Galveston

NCT00693173

Phase Distribution

PhaseTrial count
Phase 1 5
Phase 2 5
Phase 3 2

Named interventions

Most-linked intervention names on Anal Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

M7824 Biological
2 trials
fluorouracil Drug
2 trials
Pembrolizumab Drug
2 trials
Open, traditional approach Procedure
1 trials
Videoscopic procedure Procedure
1 trials
mitomycin C Drug
1 trials
laser therapy Device
1 trials
thermal ablation therapy Device
1 trials

US sites by state

Facility locations filed on Anal Cancer trials. A trial with sites in several states counts in each.

Maryland 6 trials
Illinois 5 trials
Massachusetts 4 trials
Florida 4 trials
Colorado 4 trials
California 4 trials
Texas 3 trials
Pennsylvania 3 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Anal Cancer page

21 registered trials, 9 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Anal Cancer condition card totals 21 registered trials; most-linked intervention M7824; top US site state Maryland. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.